ÂÜÀòÂÒÂ×

M. (Venkat) Venkatraman, PhD has over ten years of drug discovery and preclinical development experience. He was formerly Senior Scientist Chemistry at CoMentis Inc. where he was one of the key inventors of ATG-052, a development candidate for the alpha7 nicotinic acetylcholine receptor agonist program for cognition enhancement. Previously, Dr. Venkatraman was Senior Scientist at Portola Pharmaceuticals where he was one of the inventors of PRT-083, a potent reversible P2Y12 receptor antagonist for the treatment of thrombosis in patients with acute coronary syndrome. Earlier in his career, Dr. Venkatraman was Scientist at Millennium Pharmaceuticals as well as at Cor Therapeutics (prior to its merger with Millennium) working on transforming growth factor β as a target for fibrosis and cancer.

Dr. Venkatraman received a PhD at the National Chemical Laboratory, Pune, India in the field of synthetic organic chemistry and pursued postdoctoral research at M.D. Anderson Cancer Center, Houston. He is an inventor on 6 US patents and patent applications.